EUVIMEDEUVIMED entdecken
Vergleichsstudie

Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD)

Pedro H Reis-Barbosa iD, Carlos A Mandarim-de-Lacerda iD

Fundamental & Clinical Pharmacology · 2024

DOI: 10.1111/fcp.13024 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Fundamental & Clinical Pharmacology, 2024. Verfasst von Pedro H Reis-Barbosa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Morphometry, Metabolism and Cardiovascular Diseases, Biomedical Center, The University of the State of Rio de Janeiro, Rio de Janeiro, …. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl-Peptidase IV Inhibitors, Mice, Inbred C57BL, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Monotherapy to treat obesity‐associated liver insult is limited.

Objectives

In diet‐induced obese mice showing metabolic dysfunction‐associated steatotic liver disease (MASLD), we aimed to compare the combinations of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i, empagliflozin, E), dipeptidyl peptidase‐4 inhibitor (DPP4i, linagliptin, L), and glucagon‐like peptide type 1 receptor agonist (GLP1RA, dulaglutide, D).

Methods

Male 3‐month‐old C57BL/6J mice were fed for 12 weeks in a control (C, n = 10) or high‐fat (HF, n = 30) diet. Then, mice were followed for three additional weeks: C, HF, HF E + L, and HF E + D ( n = 10/group).

Results

HF versus C showed higher hepatic triacylglycerol (TAG, +82%), steatosis (+850%), glucose intolerance (+71%), insulin (+98%), and insulin resistance (+68%). Compared to the HF group, HF E + L showed lower glucose intolerance (−60%), insulin (−61%), insulin resistance (−46%), TAG (−61%), and steatosis (−58%), and HF E + D showed lower glucose intolerance (−71%), insulin (−58%), insulin resistance (−62%), TAG (−61%), and steatosis (−82%). The principal component analysis (PCA) placed the HF group and the HF E + D group on opposite sides, while the HF E + L group was placed between C and HF E + D.

Conclusion

PCA separated the groups considering the metabolism‐related genes (glucose and lipid), mitochondrial biogenesis, and steatosis. The two pharmacological combinations showed beneficial effects in treating obesity and MASLD. However, the combination of SGLT2i and GLP1RA showed more potent beneficial effects on MASLD than SGLT2i and DPP4i and, therefore, should be the recommended combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsMice, Inbred C57BLGlucagon-Like Peptide-1 Receptor AgonistsAnimalsMaleMiceObesityFatty LiverDrug Therapy, CombinationMice, ObeseDiet, High-FatLinagliptinGlucosidesBenzhydryl Compounds

Stichwörter der Autor:innen

beta‐oxidationinflammationlipogenesismetabolic dysfunction‐associated steatotic liver diseaseobesity

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsLinagliptinempagliflozinGlucosidesBenzhydryl CompoundsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Laboratory of Morphometry, Metabolism and Cardiovascular Diseases, Biomedical Center, The University of the State of Rio de Janeiro, Rio de Janeiro, Brazil.

ORCID-Profile: Pedro H Reis-Barbosa, Carlos A Mandarim-de-Lacerda

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

Zitieren

APA

Reis-Barbosa, P. H., & Mandarim-de-Lacerda, C. A. (2024). Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD). Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.13024

Vancouver

Reis-Barbosa PH, Mandarim-de-Lacerda CA. Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD). Fundamental & Clinical Pharmacology. 2024. doi:10.1111/fcp.13024

BibTeX
@article{ReisBarbosa2024,
  author = {Reis-Barbosa, Pedro H and Mandarim-de-Lacerda, Carlos A},
  title = {Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD)},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/fcp.13024}
}
Kostenlos starten →